Clinical Trial Update: Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 placebo-controlled trial of ONO-2333Ms in patients with recurrent major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• ONO-2333Ms

Snippet

Sponsor: Ono Pharma USA Inc | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED